What is APRE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for APRE?

P/E (TTM) is n/a and 52-week range is $0.55 to $1.69 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s APRE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for APRE?

The company profile lists revenue (TTM) near $1K, net income (TTM) near $-5M, EPS (TTM) near $-1.08 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Aprea Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Doylestown, Pennsylvania, US, 12.4M shares outstanding, ISIN US03836J2015 when available from company profile and filing metadata.

Aprea Therapeutics Inc

$APRE

Health Care · Biotechnology

IR Run Scenarios

$0.60

+8.28%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2019-10-03. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. The company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. The company also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Employees

Website

www.aprea.com/

IPO

2019-10-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)